Report
Alexander Makar ...
  • Bart Cuypers
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

KBC Securities Morning Note 30-11-2018 ABN NA, AED BB, CYAD BB, ELI BB, MIKO BB

ABN Amro: A warning and A wish
Aedifica: New € 4m acquisition in Germany
Celyad: CYAD-101 1st patient dosed, all rights back to Celyad
Elia Group: German FY18 financial outlook raised slightly
Miko: Taking over Norwegian company Kaffebryggeriet
Underlyings
ABN AMRO Bank NV Depositary receipts

ABN Amro Bank NV is a bank based in the Netherlands. The Bank provides various financial products and services across a variety of channels, including its Mobile Banking app and Internet Banking. The Bank's product portfolio includes insurances, mortgages, savings, investments, loans and payments, among others. The Bank serves retail, private and corporate clients worldwide.

Aedifica SA

Aedifica is a property company, which is specialized in residential real estate. Co.'s portfolio has a superstructure of more than 225,911 sq. m as of June 30 2010. It owns: residential or mixed buildings in Belgian cities with classical leases; buildings with furnished apartments buildings in the heart of Brussels with shorter term leases; senior houses and serviceflats with very long term and triple net leases; and hotels. Co. invests: in existing and already leased buildings; and in projects with future completion. Co.'s activities can be divided into four segments: Residential or mixed buildings; Furnished apartments buildings; Senior houses; and Hotels and others.

Celyad Oncology

Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.

Elia Group SA/NV

Elia System Operator develops, operates and maintains very-high-voltage (380 kV, 220 kV and 150 kV) and high-voltage (70 kV, 36 kV and 30 kV) networks, providing its customers with consultancy and engineering services. Whether in Belgium, Germany or elsewhere in Europe or the U.S., Co. ensures that electricity flows reliably from energy producers to distributors and large corporate customers. Co.'s main activities include transmission operator, system operator and market facilitator, developing and maintaining grid infrastructure, connecting electrical installations to grids, providing transparent access to grids, while taking initiatives to improve electricity market operations.

Miko N.V.

Miko SA. Miko NV is a Belgium-based company that is engaged coffee and snacks service and plastic packaging sectors. The Company's coffee segment delivers Its products to the out-of-home market, such as coffee, fruits, water and other beverages, snacks and sweets that are consumed outside the private home, in places like offices, businesses and restaurants. Within the Plastics segment, the Company manufactures plastic packaging products, among others for the food industry and the homecare sector, such as bubble wraps for laundry detergent. Miko NV has subsidiaries in the United Kingdom, France, the Netherlands, Germany, Poland, the Czech Republic, Slovakia, Sweden, Denmark and Australia. It also sells its coffee concepts through independent distributors in thirty countries in Europe, among others.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Alexander Makar

Bart Cuypers

Cedric Duinslaeger

Guy Sips

Jan Opdecam

Jason Kalamboussis

Lenny Van Steenhuyse

Sandra Cauwenberghs

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch